Neuroendocrine Differentiation of Primary Mucinous Carcinoma of the Cheek Skin

1. Feingold M. 28-year follow-up of the craniofacial findings in a patient with craniometaphyseal dysplasia. Am J Med Genet 1999;86:501-2. 2. Jackson WP, Albright F, Drewry G, et al. Metaphyseal dysplasia, epiphyseal dysplasia, diaphyseal dysplasia, and related conditions. I. Familial metaphyseal dysplasia and craniometaphyseal dysplasia; their relation to leontiasis ossea and osteopetrosis; disorders of bone remodeling. AMA Arch Intern Med 1954;94:871-85. 3. Beighton P. Craniometaphyseal dysplasia (CMD), autosomal dominant form. J Med Genet 1995;32:370-4. 4. Lamazza L, Messina A, D'Ambrosio F, et al. Craniometaphyseal dysplasia: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2009;107:e23-7. 5. Richards A, Brain C, Dillon MJ, et al. Craniometaphyseal and craniodiaphyseal dysplasia, head and neck manifestations and management. J Laryngol Otol 1996;110: 328-38. Primary mucinous carcinoma of the skin (MCS) is a rare sweat gland tumor, with approximately 175 cases reported in the literature since the first case was described by Lennox et al. [1] in 1952. Although MCS is usually slow growing, it often shows locally aggressive behavior and a high rate of local recurrence following simple excision. The clinical appearance and differential diagnosis of MCS vary, but histopathologically MCS is similar to metastatic carcinomas, specifically of the breast and colon. The recognition of MCS is essential for preventing an erroneous diagnosis of Neuroendocrine Differentiation of Primary Mucinous Carcinoma of the Cheek Skin